therapeutic drug monitoring – Page 2

Peritoneal dialysis-related peritonitis caused by Fusarium: a case report and literature review

mycolabadmin

A 61-year-old farmer with kidney disease on peritoneal dialysis developed a rare fungal infection caused by Fusarium, a fungus found in soil and water. After initial antibiotics failed, doctors identified the fungus and switched to an antifungal medication called voriconazole. By carefully monitoring drug levels in the patient’s blood and adjusting doses, pharmacists helped achieve a successful recovery with complete resolution of symptoms.

Antifungal stewardship in the UK: where are we now?

mycolabadmin

Fungal infections are becoming more common and dangerous because some fungi are developing resistance to antifungal medicines. UK hospitals struggle to manage these infections due to lack of funding, staffing, and limited access to fungal testing services. The paper recommends creating regional fungal expertise centers and setting national standards to improve how antifungal medications are used and monitored across the country.

Isavuconazole: Need for therapeutic drug monitoring and CYP polymorphism testing

mycolabadmin

A patient with a serious fungal infection of the sinuses caused by Rhizopus arrhizus received the antifungal drug isavuconazole. However, blood tests showed the drug was building up to dangerously high levels in her body. Genetic testing revealed she had a mutation that made her body unable to break down the drug normally. The doctors had to give her much smaller and less frequent doses while carefully monitoring her drug levels to keep her safe.

Approaches to Invasive Fungal Diseases in Paediatric Cancer Centres: An Analysis of Current Practices and Challenges in Germany, Austria and Switzerland

mycolabadmin

This research examined how pediatric cancer hospitals in Germany, Austria, and Switzerland manage fungal infections, which are a serious risk for children undergoing cancer treatment. The survey found that while most hospitals have infection specialists and antifungal prevention strategies, there are significant differences in how they diagnose and treat these infections. The study identified key challenges like drug interactions and delays in testing, and suggests that better networks between cancer and infection specialists could improve patient care.

Histoplasma capsulatum prosthetic valve endocarditis treated with oral isavuconazole

mycolabadmin

A 76-year-old man developed a rare fungal infection of his artificial heart valve caused by Histoplasma capsulatum. After surgically replacing the infected valve, he was treated with isavuconazole, an antifungal medication taken by mouth. Unlike traditional antifungal treatments, isavuconazole was better tolerated and easier to take. The patient successfully recovered after nine months of treatment with no complications.

Candida krusei Empyema: A Lung Transplant Case and Systematic Review of the Literature

mycolabadmin

Candida krusei is a dangerous fungus that can cause fluid buildup around the lungs (empyema), particularly in transplant patients. Unlike common fungal infections that respond to fluconazole, this species is naturally resistant to this drug, making it harder to treat. The fungus forms protective biofilms that shield it from treatment, requiring combination antifungal medications and sometimes surgery to drain the fluid and remove infected tissue for successful recovery.

A case report of disseminated histoplasmosis not responding to primary treatment by itraconazole

mycolabadmin

A healthy 28-year-old woman developed a serious fungal infection caused by Histoplasma capsulatum after dental surgery. The standard antifungal medication (itraconazole) did not work for her, even at high doses. Doctors successfully treated her with a more powerful antifungal drug called liposomal amphotericin B, which cleared the infection completely. This case shows the importance of adjusting treatment when patients don’t respond to initial therapy.

A case report of disseminated histoplasmosis not responding to primary treatment by itraconazole

mycolabadmin

A 28-year-old woman developed a serious fungal infection (histoplasmosis) after dental surgery that was initially misdiagnosed as a bacterial infection. Although she was treated with an antifungal medication called itraconazole, her condition worsened with larger lung lesions appearing. When switched to a stronger intravenous antifungal called liposomal amphotericin B, she rapidly improved and fully recovered, demonstrating the importance of adjusting treatment when patients don’t respond as expected.

Isavuconazonium Utilization in Pediatric Patients at a Free-Standing Children’s Hospital

mycolabadmin

Researchers at Children’s Hospital Los Angeles studied how well a newer antifungal medication called isavuconazonium works in children with cancer and blood disorders who are at high risk for serious fungal infections. The medication was recently approved for use in children ages 1 and older. The study found that the medication was generally safe and effective, though doctors need to monitor liver function and drug levels to ensure proper dosing and catch any side effects early.

Antifungal Agents in the 21st Century: Advances, Challenges, and Future Perspectives

mycolabadmin

This review examines how doctors treat serious fungal infections and the growing problem of fungi becoming resistant to medications. The authors discuss different antifungal drugs, how they work, and why some fungi are becoming harder to treat. They emphasize that controlling fungal resistance requires coordinated efforts across hospitals, farms, and communities, especially since some agricultural pesticides are creating resistant strains that spread to sick patients.

Research Keyword: therapeutic drug monitoring